J&J’s Biosense Webster Launches OPTRELL Mapping Catheter

Biosense Webster, a J&J MedTech company, has launched its OPTRELL mapping catheter with TRUEref tech powered by the CARTO 3 system in the U.S. OPTRELL earned FDA clearance in 2022.
 
The high-density diagnostic catheter has small electrodes in a fixed array formation. This provides high-definition electrophysiological mapping for complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.
 
OPTRELL contains 48 electrodes symmetrically arranged and along six splines with the CARTO 3 system to provide intelligent insights and high-res directional mapping. The catheter’s tight electrode spacing and small electrodes produce higher signal resolution for enhanced heart maps.
 
Using the high-def maps, clinicians can better understand where the arrhythmia is occurring, and develop a better ablation strategy.
 
“The OPTRELL Mapping Catheter has a fixed electrode array structure that provides greater diagnostic insight, which allows physicians to quickly and effectively identify ablation targets,” Pasquale Santangeli, M.D., Ph.D., Cardiovascular Medicine, Cleveland Clinic Main Campus, told the press. “This catheter and the Local Conduction Vectors give me the confidence to quickly and effectively detect ablation lesion gaps and the arrhythmia substrate, even in the most complex cases, including persistent AFib, redo AFib ablation, atrial tachycardia, and ventricular tachycardia.”
 
The CARTO 3 system, offers Local Conduction Vectors that display the real-time direction and speed of the electrical impulses traveling through the heart. With these Local Conduction Vectors, J&J says clinicians gain enhanced understanding of complex circuits and mechanisms and can confidently detect gaps in ablation lesions.
 
“The OPTRELL Mapping Catheter rounds out the Biosense Webster diagnostic mapping portfolio, providing physicians with a comprehensive set of tools, integrated with our CARTO 3 mapping system, to diagnose and treat arrhythmias,” said Jasmina Brooks, president, Biosense Webster, Inc. “This is the latest example of the continued commitment of Biosense Webster to providing clinicians with innovative tools to improve efficiency and effectiveness of procedures and quality of care for patients.”